Clinical progress and transmission perils stressed at second human retroviruses conference.
Mascolini
M
M
D016915:AIDS Vaccines; D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control; D000212:Acyclovir / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D006564:Herpesviridae / Q000302:isolation & purification; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D019259:Lamivudine; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D012190:Retroviridae; D012514:Sarcoma, Kaposi / Q000821:virology; D016047:Zalcitabine / Q000627:therapeutic use; D015215:Zidovudine / Q000627:therapeutic use
D016915:AIDS Vaccines; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D007376:Interleukin-2; D019259:Lamivudine; D015215:Zidovudine; D016047:Zalcitabine; D000212:Acyclovir